The EPS projection of The Medicines Company (NASDAQ:MDCO) for quarter ended 2016-09-30 is $-1.12. A week before, the EPS forecast was $-1.12 against target of $-1.12, a month earlier. This estimate stood at $-1.12 60 days earlier versus forecast of $-1.12 90 days earlier, confirming a deviation of 0%.
The Medicines Company (NASDAQ:MDCO) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 1, 0 and 1, respectively.
The downgrade of EPS estimates for The Medicines Company (NASDAQ:MDCO) in the preceding 120, 60, 30 and 90 days were 1, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of The Medicines Company (NASDAQ:MDCO) was $-1.12. This projection was computed after accounting 3 calls. As reported on 2016-05-09 the EPS was $-1.13. The change was $-0.28, demonstrating a percentage deviation of -32.94%. The projections confirmed a standard deviation of 0.08.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for The Medicines Company (NASDAQ:MDCO) stands at $38.35 and the median estimate at $38.35. Almost 2 analysts announced their estimates.
The highest estimate is $39.5 while the lowest target is $37.2 showing standard deviation of 1.626%.
As many as 2 analysts released sales estimates reised in upside while 2 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 2 revised sales number projection on upside while 2 lowered the sales target, demonstrating a deviation of -10.606%.
A quarter ago, 2 hiked sales estimations and 2 reduced sales forecast. The Medicines Company (NASDAQ:MDCO) stated that the change in forecast was -26.179%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...